Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of atacicept compared to
placebo in the treatment of signs and symptoms in a subject population with active rheumatoid
arthritis (RA), inadequate response to methotrexate (MTX) and no previous exposure to
anti-tumor necrosis factor alpha (anti-TNFalpha) therapy.